• 07 APR 14

    About ICCD

    Established in October 2012, company aims R & D of innovative medical diagnostic technology, based on FTIR microspectroscopy for in vitro cancer diagnosis and on fiber optics IR spectroscopy for in vivo cancer diagnosis. Company plans development of new diagnostic criteria for cancerous diseases and their implementation in the hospital for monitoring therapeutical effect, that will find use for developing personalized medicine and for guidance of drug development in pharma.

    Basic idea:
    IR spectroscopy has been proven to characterize cellular abnormalities related to a variety of cancers from different organs. IR microspectroscopy offers a number of advantages to analyse human tissues over existed «gold standard», a histopathological method, in vitro. IR microspectroscopy is used on the unstained tissues, it has a high sensitivity to provide qualitative and quantitative information of proteins, nucleic acids, lipids and other biomolecules on the molecular level, suitable for differentiation between healthy and cancerous tissues. IR spectral diagnosis offers a development of biomarkers, pattern recognition by means of characterization of
    nucleic acids and proteins in the tissue, alone and in combination.

    Company aim:
    Development of a novel non-invasive diagnostic method, suitable to follow-up diagnosis and efficacy of therapeutic effect(s) directly on the patients with different cancer types.

    Core person:
    Natalja Eikje, with M.D. and Ph.D. in dermatology, is responsible for management at ICCD since 2012. A 15-year of international experience as a Project Manager in multi-disciplinary teams in Denmark, Holland and Japan.

    PARTNERS, COLLABORATORS: MC Professional OÜ (Tallinn, Estonia); Histalim SARL (Montpellier, France); LINK Medical Research AS (Oslo, Norway); Innokas Medical Oy (Kempele, Finland), HiOA (Oslo and Akershus University College)